Streetwise Articles


Maxim's Target Price on Biotech Makes It More Than a Tenbagger

Research Report
  ()
Jason Kolbert, an analyst with Maxim Group, provided an update on this biopharmaceutical firm's two recently acquired oncology assets. read more >

'Hot' Alzheimer's Market is Promising for Biotech with 'Novel' Drug Candidate

Research Report
  ()
André Uddin, an analyst with Mackie Research Capital Corp., summarized the quarterly financial results and anticipated catalysts for this Alzheimer's drug developer. read more >

Biotech's Target Price Increased as Shares 'Deeply Undervalued'

Research Report
  ()
Wedbush analyst Robert Driscoll provided an update on the lead asset of this drug developer targeting cancer. read more >

Biotech Targets 'Blockbuster' Markets; Less-Addictive Opioid Painkiller Set for FDA Filing

Contributed Opinion
  ()
Medical Technology Stock Letter editor John McCamant outlines the reasons behind the buy rating and target price increases for a company that, in addition to developing an alternative to addictive opioids for pain relief, has candidates targeting multiple immune disorders and cancer. read more >

The Lowdown on Getting High in Canada

Contributed Opinion
  ()
Some 600 tonnes of marijuana a year are up for grabs as Canada moves to legalize weed, says Rick Mills, founder of Ahead of the Herd, who puts forth his case on why cannabis stocks should be in every investor's portfolio. read more >

Biotech with Solid Pipeline and 'Solid Partnership Outlook'

Research Report
  ()
Analyst Kevin DeGeeter, with Ladenburg Thalmann, relayed the highlights from his recent meeting with this company's management team about near-term clinical news and pipeline plans. read more >

Analyst Says Biotech Share Price Could Potentially 'Double'

Research Report
  ()
Analyst Grant Zeng of Zacks Small Cap Research examines what transpired with this biopharmaceutical company during Q3/17. read more >

Could a FDA Warning Letter Provide a Silver Lining to This Home Care Medical Device Company?

Contributed Opinion
  ()
Maj Soueidan, cofounder of GeoInvesting, profiles his long history with a company providing medical devices for the home care market. read more >

Biotech Reports Positive Topline Data; Biologics License Application in Progress

Research Report
  ()
Ram Selvaraju, an analyst with H.C. Wainwright & Co., reviewed the recent clinical trial results released by this developer of cell therapies targeting oncology and orphan indications. read more >

Target Price Raised on 'Undervalued' Antibiotics Developer

Research Report
  ()
Analyst Ed Arce discussed the rationale behind H.C. Wainwright & Co.'s decision to revise its models on this clinical-stage biopharmaceutical company. read more >

Drug Offers 'Best-in-Class' Potential

Contributed Opinion
  ()
John McCamant, editor of the Medical Technology Stock Letter, initiated coverage on a company that he calls an emerging leader in women's health. read more >

Big Biotech's Value Is Bolstered by Focus on Alzheimer's Disease

Research Report
  ()
An analysis of this company's quarterly update highlights a pipeline studded with candidates targeting neurological indications. read more >

Biotech Receives Device Approval in Five More Countries; Revenue Up 122% YOY

Research Report
  ()
Maxim Group reported on this firm's Q3/17 earnings, as well as its progress in obtaining international regulatory clearances for its medical system. read more >

Biopharmaceutical Firm Receives FDA Priority Review and PDUFA Date

Research Report
  ()
Neil Maruoka, an analyst with Canaccord Genuity, provided an update on this biotech's progress through the regulatory approval process for one of its therapeutics. read more >

Analyst Calls Biotech with Alzheimer's Therapy a 'High Risk, High Reward Opportunity'

Research Report
  ()
Mackie Research reported on this company's recent announcement about one of its product candidates targeting Alzheimer's disease. read more >

Coverage Initiated on Gene Therapy Company

Research Report
  ()
Analyst David Nierengarten with Wedbush explained the rationale for adding this biotech to his coverage universe. read more >

Biotech Announces 'Late-Breaking' Addition to Immunotherapy Conference

Research Report
  ()
Michael King Jr., an analyst with JMP Securities, reported this biopharmaceutical firm was recently added to the roster of presenters scheduled for an upcoming annual meeting. read more >

Biotech Releases Initial Zika Vaccine Trial Results; Advances Combo Trials

  ()
With multiple candidates in the pipeline advancing through clinical trials, Ram Selvaraju, an analyst with H.C. Wainwright & Co., provided insight into developments at a biotech addressing Zika virus, advanced bladder cancer and cervical dysplasia. read more >

Reliq Health Technologies Quickly Gaining Traction in Fast Growing Telemedicine Market

  ()
The rapid increase in the incidence of chronic diseases and the need to reduce healthcare costs have led to the growth in telemedicine, and Reliq Health Technologies is adding thousands of patients to its rolls. read more >

Cannabis Company Forms Partnership to Develop Pharmaceuticals

Research Report
  ()
Analyst Russell Stanley with Echelon Wealth Partners explained the significance of the recent licensing agreement signed by this Canadian medical marijuana producer and distributor. read more >

Telemedicine Platform Is Quickly Gaining Traction in Fast Growing Market

  ()
The rapid increase in the incidence of chronic diseases and the need to reduce healthcare costs have led to the growth in telemedicine, which has companies racing to bring new products to market. read more >

Reliq Health Technologies Quickly Gaining Traction in Rapidly Growing Telemedicine Market

  ()
The rapid increase in the incidence of chronic diseases and the need to reduce healthcare costs have led to the growth in telemedicine, which has companies racing to bring new products to market. read more >

Japan Is Fertile Ground for Biotech Deals

  ()
Japan and the United States are hotspots for companies that are looking to license-out exciting regenerative medicine technology, says Colin Lee Novick, managing director of CJ PARTNERS. In this interview with The Life Sciences Report, Novick discusses a regenerative medicine company pursuing partnerships in Japan for its cell therapies to treat chronic tendinosis, damaged or aged skin, and pattern baldness. read more >

Small Biotech Enters Patent Deal with British Company Targeting Schizophrenia

  ()
A small-cap American biotech has secured a patent agreement with a larger British firm, garnering the attention of three sector analysts. read more >
Management Q&A: View from the Top

Biotech with Transformative RNAi Delivery System Set for Multiple Catalysts by Year-End

Managment Q&A: View from the Top
  ()
With data from multiple studies due out this quarter, this biotech's RNA interference delivery platform has the potential to transform treatments for indications from cancer to ophthalmology, says Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, Dr. Gerrit Dispersyn, RXi's Chief Development Officer, and Dr. Karen Bulock, Vice President of Research at RXi. read more >
Showing Results: 26 to 50 of 222 Prev Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe

More Experts